https://www.pharmaradar360.com/article/must-see-museums-the-heritage-gallery-f8ae478aab63fcf2PharmaRadar360en2026-09-15T16:34:39.000ZMust See Museums: The Heritage Galleryhttps://www.pharmaradar360.com/article/minnesota-healthcare-providers-detail-harm-to-patients-from-operation-metro-surg-1431dfd58da5f22fPharmaRadar360en2026-09-15T16:34:17.000ZMinnesota healthcare providers detail harm to patients from Operation Metro Surgehttps://www.pharmaradar360.com/article/minnesota-private-well-owners-are-largely-on-their-own-when-it-comes-to-arsenic-592a54313504782cPharmaRadar360en2026-09-15T16:33:52.000ZMinnesota private well owners are largely on their own when it comes to arsenichttps://www.pharmaradar360.com/article/what-a-federal-mail-in-ballot-proposal-means-for-minnesota-voters-37e175b0fe4b7083PharmaRadar360en2026-09-15T16:33:19.000ZWhat a federal mail-in ballot proposal means for Minnesota votershttps://www.pharmaradar360.com/article/planning-to-repair-your-lawn-this-fall-here-s-what-you-need-to-know-7863c5bdc59effd1PharmaRadar360en2026-09-15T16:32:25.000ZPlanning to repair your lawn this fall? Here's what you need to knowhttps://www.pharmaradar360.com/article/jd-vance-s-catholicism-could-be-at-odds-with-maga-evangelicals-in-2028-92a05500444ddfe5PharmaRadar360en2026-09-15T16:31:56.000ZJD Vance’s Catholicism could be at odds with Maga evangelicals in 2028https://www.pharmaradar360.com/article/the-energy-uc-irvine-never-used-47d02add849c9ba3PharmaRadar360en2026-09-15T16:21:55.000ZThe energy UC Irvine never usedhttps://www.pharmaradar360.com/article/ich-kann-zeigen-was-ich-kann-schon-in-jungem-alter-bd19b1665f8d76d6PharmaRadar360en2026-09-15T16:04:36.000Z«Ich kann zeigen, was ich kann – schon in jungem Alter.»https://www.pharmaradar360.com/article/how-queueing-science-could-fix-hub-staffing-guesswork-8b1c0f65b7491859PharmaRadar360en2026-09-15T16:01:46.000ZHow Queueing Science Could Fix Hub Staffing Guessworkhttps://www.pharmaradar360.com/article/official-statistics-quarterly-reports-on-the-import-of-unlicensed-medicines-ad6b052d146f111aPharmaRadar360en2026-09-15T15:57:35.000ZOfficial Statistics: Quarterly reports on the import of unlicensed medicineshttps://www.pharmaradar360.com/article/waltham-biotech-cuts-nearly-half-its-workforce-after-cystic-fibrosis-drug-fails-154605cf755a25bfPharmaRadar360en2026-09-15T15:53:00.000ZWaltham biotech cuts nearly half its workforce after cystic fibrosis drug failshttps://www.pharmaradar360.com/article/ori-biotech-signs-10-year-120m-deal-to-automate-commercial-cell-therapy-manufact-adbe486e7d89146bPharmaRadar360en2026-09-15T15:52:25.000ZOri Biotech signs 10-year, $120M deal to automate commercial cell therapy manufacturinghttps://www.pharmaradar360.com/article/guy-s-pharmacy-launches-medicine-collection-lockers-81967b05e661e7b2PharmaRadar360en2026-09-15T15:44:27.000ZGuy’s pharmacy launches medicine collection lockershttps://www.pharmaradar360.com/article/convenio-de-colaboracion-con-la-defensoria-de-la-ninez-bee014f00dc8db5cPharmaRadar360en2026-09-15T15:38:32.000ZConvenio de colaboración con la Defensoría de la Niñezhttps://www.pharmaradar360.com/article/la-estudiante-que-representara-al-pais-en-un-congreso-aeroespacial-visito-el-rec-6eb1e2fe926ccbe3PharmaRadar360en2026-09-15T15:38:24.000ZLa estudiante que representará al país en un congreso aeroespacial visitó el Rectoradohttps://www.pharmaradar360.com/article/constituimos-la-mesa-de-computacion-cuantica-89b47da77220d081PharmaRadar360en2026-09-15T15:37:41.000ZConstituimos la Mesa de Computación Cuánticahttps://www.pharmaradar360.com/article/science-entrepreneur-philip-goelet-joins-whitehead-institute-board-of-directors-73e5ecc85fa4e229PharmaRadar360en2026-09-15T15:35:00.000ZScience entrepreneur Philip Goelet joins Whitehead Institute Board of Directorshttps://www.pharmaradar360.com/article/ubc-researchers-awarded-1m-wall-fellowships-to-advance-human-and-ecosystem-healt-44c569f2963ac6a1PharmaRadar360en2026-09-15T15:30:00.000ZUBC researchers awarded $1M Wall Fellowships to advance human and ecosystem healthhttps://www.pharmaradar360.com/article/material-de-lectura-8517301ac515699dPharmaRadar360en2026-09-15T15:28:40.000ZMaterial de Lecturahttps://www.pharmaradar360.com/article/concursos-nodocentes-983118a1cfff9744PharmaRadar360en2026-09-15T15:28:33.000ZConcursos NoDocenteshttps://www.pharmaradar360.com/article/concursos-presidencia-0738a9ef10c73b04PharmaRadar360en2026-09-15T15:28:04.000ZConcursos Presidenciahttps://www.pharmaradar360.com/article/le-micro-de-la-maternite-un-podcast-pour-s-informer-sur-sa-grossesse-53d9972b3d11bf70PharmaRadar360en2026-09-15T15:19:31.000Z« Le Micro de la Maternité » : un podcast pour s'informer sur sa grossessehttps://www.pharmaradar360.com/article/new-partnership-creates-pathway-from-clarkson-college-to-unmc-pharmacy-programs-fbb78b823002db73PharmaRadar360en2026-09-15T15:08:11.000ZNew partnership creates pathway from Clarkson College to UNMC Pharmacy programshttps://www.pharmaradar360.com/article/fda-accepts-curi-bio-s-letter-of-intent-into-istand-program-to-qualify-3d-neurom-00b00f0510c84820PharmaRadar360en2026-09-15T15:06:15.000ZFDA Accepts Curi Bio’s Letter of Intent into ISTAND Program to Qualify 3D Neuromuscular Junction Assay as a Non-Animal Replacement for Botulinum Toxin Potency Testinghttps://www.pharmaradar360.com/article/smelling-chocolate-helped-men-complete-more-reps-without-feeling-more-tired-d83c990ebb92dc03PharmaRadar360en2026-09-15T15:03:54.000ZSmelling chocolate helped men complete more reps without feeling more tiredhttps://www.pharmaradar360.com/article/q-a-a-playbook-for-dscsa-value-beyond-compliance-eb0d87a1e73b22edPharmaRadar360en2026-09-15T15:02:21.000ZQ&A: A Playbook for DSCSA Value Beyond Compliancehttps://www.pharmaradar360.com/article/abbvie-named-official-pharmaceutical-sponsor-of-the-pga-tour-and-2026-presidents-2e56b8e582b343faPharmaRadar360en2026-09-15T14:59:17.000ZAbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaignhttps://www.pharmaradar360.com/article/abbvie-and-biolabs-university-of-toronto-open-applications-for-abbvie-biotech-in-75f7dce44dd8df60PharmaRadar360en2026-09-15T14:58:57.000ZAbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forumhttps://www.pharmaradar360.com/article/uk-advisory-panel-ukap-enquiry-form-38f5d243521e9931PharmaRadar360en2026-09-15T14:52:58.000ZUK Advisory Panel (UKAP): enquiry formhttps://www.pharmaradar360.com/article/imvax-announces-additional-data-from-phase-2b-clinical-trial-of-igv-001-in-newly-d5d0f8a72497251bPharmaRadar360en2026-09-15T14:48:12.000ZImvax Announces Additional Data from Phase 2b Clinical Trial of IGV-001 in Newly Diagnosed GBM and Provides Update on Planned Clinical Developmenthttps://www.pharmaradar360.com/article/the-biotech-industry-wrote-montana-s-right-to-try-law-now-they-re-running-the-sh-d462381332cb2633PharmaRadar360en2026-09-15T14:44:00.000ZThe biotech industry wrote Montana's right-to-try law. Now they're running the show.https://www.pharmaradar360.com/article/student-entrepreneurs-vie-for-35k-shark-tank-style-f9820b04c2555df4PharmaRadar360en2026-09-15T14:41:52.000ZStudent entrepreneurs vie for $35K, ‘Shark Tank’-stylehttps://www.pharmaradar360.com/article/intermountain-health-primary-children-s-hospitals-once-again-ranked-among-nation-002824e58ab7f154PharmaRadar360en2026-09-15T14:41:43.000ZIntermountain Health Primary Children's Hospitals Once Again Ranked Among Nation's Best in All 11 Pediatric Specialties by U.S. News & World Reporthttps://www.pharmaradar360.com/article/new-haven-biotech-raises-33m-for-cancer-drug-development-73485c033219a385PharmaRadar360en2026-09-15T14:39:41.000ZNew Haven biotech raises $33M for cancer drug developmenthttps://www.pharmaradar360.com/article/data-driven-envirolab-team-maps-the-heat-06daa6d460a43865PharmaRadar360en2026-09-15T14:38:40.000ZData-Driven EnviroLab team maps the heathttps://www.pharmaradar360.com/article/fda-hears-80-speakers-on-psychedelic-drug-therapy-standards-08469c1399c0a84aPharmaRadar360en2026-09-15T14:33:42.000ZFDA Hears 80 Speakers on Psychedelic Drug Therapy Standardshttps://www.pharmaradar360.com/article/scientists-discover-a-major-brain-shift-between-ages-50-and-75-aa4a9d132a2808caPharmaRadar360en2026-09-15T14:28:38.000ZScientists discover a major brain shift between ages 50 and 75https://www.pharmaradar360.com/article/abbvie-and-biolabs-university-of-toronto-open-applications-for-abbvie-biotech-in-4f7584c7886f13aaPharmaRadar360en2026-09-15T14:27:30.000ZAbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forumhttps://www.pharmaradar360.com/article/agentic-ai-trust-gap-slowing-healthcare-provider-adoption-survey-reveals-c9537e83af37e3d8PharmaRadar360en2026-09-15T14:24:58.000ZAgentic AI trust gap slowing healthcare provider adoption, survey revealshttps://www.pharmaradar360.com/article/gsk-to-acquire-potential-best-in-class-t-cell-engager-tce-for-multiple-myeloma-f-62e7d22436b47e77PharmaRadar360en2026-09-15T14:21:27.000ZGSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Bioscienceshttps://www.pharmaradar360.com/article/supporting-complex-phase-i-studies-through-integrated-imaging-and-specialized-as-0e0c38380763ff9cPharmaRadar360en2026-09-15T14:15:39.000ZSupporting Complex Phase I Studies Through Integrated Imaging and Specialized Assessmentshttps://www.pharmaradar360.com/article/defining-ad-disease-flares-vs-drug-effects-a-comparative-analysis-of-phase-3-sys-9b3a6140d8d68e9fPharmaRadar360en2026-09-15T14:14:38.000ZDefining AD Disease Flares vs. Drug Effects: A Comparative Analysis of Phase 3 Systemic Therapy Trialshttps://www.pharmaradar360.com/article/stakeholders-urge-fda-to-define-data-treatment-standards-as-psychedelic-drugs-ne-f1bbb0b0fd948389PharmaRadar360en2026-09-15T14:01:58.000ZStakeholders urge FDA to define data, treatment standards as psychedelic drugs near markethttps://www.pharmaradar360.com/article/connect-s-dupixent-rival-flunks-phase-2-asthma-trial-but-biotech-sees-reasons-fo-df8ae3f97c319dcfPharmaRadar360en2026-09-15T13:55:53.000ZConnect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hopehttps://www.pharmaradar360.com/article/obesity-drugmakers-are-testing-in-kids-as-young-as-6-15423b2c677d102aPharmaRadar360en2026-09-15T13:53:52.000ZObesity drugmakers are testing in kids as young as 6https://www.pharmaradar360.com/article/how-new-drug-trial-approvals-at-cspc-pharmaceutical-group-stock-has-changed-its-286c1b7011894676PharmaRadar360en2026-09-15T13:50:02.000ZHow New Drug Trial Approvals At CSPC Pharmaceutical Group Stock Has Changed Its Investment Storyhttps://www.pharmaradar360.com/article/oric-oric-doubles-down-on-prostate-cancer-with-phase-3-launch-f66cc21c17ead25dPharmaRadar360en2026-09-15T13:47:19.000ZORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launchhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-11-october-2026-f8d136078761e069PharmaRadar360en2026-09-15T13:45:33.000ZWeekly all-cause mortality surveillance: week ending 11 October 2026https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-42-report-data-to-week-41-data-up-t-c191b99be464c1cdPharmaRadar360en2026-09-15T13:45:31.000ZNational Norovirus and Rotavirus Report, week 42 report: data to week 41 (data up to 11 October 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-42-report-data-to-week-41-dat-81e64c216725e952PharmaRadar360en2026-09-15T13:45:28.000ZNational flu and COVID-19 surveillance report, week 42 report: data to week 41 (data up to 11 October 2026)https://www.pharmaradar360.com/article/encuentro-sobre-inmigracion-italiana-en-la-unlp-674fd69b0a715368PharmaRadar360en2026-09-15T13:44:25.000ZEncuentro sobre inmigración italiana en la UNLPhttps://www.pharmaradar360.com/article/legend-biotech-taps-novartis-veteran-zhang-as-ceo-61814d75375f6c45PharmaRadar360en2026-09-15T13:43:16.000ZLegend Biotech taps Novartis veteran Zhang as CEOhttps://www.pharmaradar360.com/article/kelun-biotech-reports-phase-iii-benefit-for-trastuzumab-botidotin-in-her2-positi-5456029ae019c373PharmaRadar360en2026-09-15T13:38:20.000ZKelun-Biotech reports Phase III benefit for trastuzumab botidotin in HER2-positive breast cancerhttps://www.pharmaradar360.com/article/scholar-rock-clarifies-post-marketing-requirements-for-isembyld-after-fda-approv-af85aacc1f2d7ef7PharmaRadar360en2026-09-15T13:30:10.000ZScholar Rock clarifies post-marketing requirements for ISEMBYLD after FDA approvalhttps://www.pharmaradar360.com/article/legend-biotech-corporation-announces-ceo-changes-22b3bb122bfb973dPharmaRadar360en2026-09-15T13:20:46.000ZLegend Biotech Corporation Announces CEO Changeshttps://www.pharmaradar360.com/article/the-overlooked-science-of-ecoa-when-good-clinical-outcome-assessments-still-prod-a1cf5235c4a8deffPharmaRadar360en2026-09-15T13:19:13.000ZThe Overlooked Science of eCOA: When Good Clinical Outcome Assessments Still Produce Poor Datahttps://www.pharmaradar360.com/article/more-than-320-pain-professionals-attended-ensysce-s-symposium-on-complex-pain-e8c78633cfca9b32PharmaRadar360en2026-09-15T13:15:00.000ZMore than 320 pain professionals attended Ensysce’s symposium on complex pain.https://www.pharmaradar360.com/article/national-cancer-plan-for-england-d59ff0423140ac07PharmaRadar360en2026-09-15T13:08:32.000ZNational Cancer Plan for Englandhttps://www.pharmaradar360.com/article/what-340b-rebate-tracking-really-demands-from-pharmacies-1036825346f0ecd9PharmaRadar360en2026-09-15T13:06:46.000ZWhat 340B Rebate Tracking Really Demands From Pharmacieshttps://www.pharmaradar360.com/article/acto-named-among-everest-group-s-top-50tm-pharmaceutical-technology-providers-fo-084ce903ab0026f7PharmaRadar360en2026-09-15T13:05:36.000ZACTO Named Among Everest Group’s Top 50™ Pharmaceutical Technology Providers for 2026https://www.pharmaradar360.com/article/fda-public-hearing-on-psychedelic-drug-therapies-sept-2026-bbfdc7e67a996d89PharmaRadar360en2026-09-15T13:02:57.000ZFDA public hearing on psychedelic drug therapies, Sept. 2026https://www.pharmaradar360.com/article/how-can-focused-ultrasound-treat-tremor-and-movement-symptoms-in-parkinson-s-dis-7207a68b37946004PharmaRadar360en2026-09-15T13:02:26.000ZHow Can Focused Ultrasound Treat Tremor and Movement Symptoms in Parkinson’s Disease?https://www.pharmaradar360.com/article/legend-names-novartis-executive-as-ceo-504f6ae79a3fda8fPharmaRadar360en2026-09-15T13:00:00.000ZLegend Names Novartis Executive as CEOhttps://www.pharmaradar360.com/article/they-had-a-plan-how-sophia-s-parents-found-care-for-rohhad-syndrome-a0e028ec4c72bb5fPharmaRadar360en2026-09-15T13:00:00.000Z‘They had a plan’: How Sophia’s parents found care for ROHHAD syndromehttps://www.pharmaradar360.com/article/uk-covid-19-inquiry-53a03ab2ca904c16PharmaRadar360en2026-09-15T12:56:05.000ZUK Covid-19 Inquiryhttps://www.pharmaradar360.com/article/what-americans-really-want-from-drug-ads-2bb4904fef97820fPharmaRadar360en2026-09-15T12:52:20.000ZWhat Americans Really Want from Drug Adshttps://www.pharmaradar360.com/article/has-group-announces-swissmedic-approval-of-cerbios-expanded-reduced-folates-prod-0e7a73cb46e0db15PharmaRadar360en2026-09-15T12:50:21.000ZHAS Group announces Swissmedic approval of Cerbios’ expanded Reduced Folates Production Unithttps://www.pharmaradar360.com/article/heilbronn-ai-virtual-networking-week-2026-dec5a1ccfcccd8e8PharmaRadar360en2026-09-15T12:48:07.000ZHeilbronn Ai Virtual Networking Week 2026https://www.pharmaradar360.com/article/legend-biotech-taps-novartis-veteran-zhang-as-ceo-2e29865224852ac9PharmaRadar360en2026-09-15T12:46:12.000ZLegend Biotech taps Novartis veteran Zhang as CEOhttps://www.pharmaradar360.com/article/legend-biotech-taps-novartis-veteran-zhang-as-ceo-151b6723d1790a16PharmaRadar360en2026-09-15T12:42:55.000ZLegend Biotech taps Novartis veteran Zhang as CEOhttps://www.pharmaradar360.com/article/co-creating-an-individual-data-return-template-a-patient-centered-approach-by-ci-8088f2b95ea81f5aPharmaRadar360en2026-09-15T12:42:49.000ZCo-Creating an Individual Data Return Template: A Patient-Centered Approach by CISCRP and Biogenhttps://www.pharmaradar360.com/article/heilbronn-ai-fellowship-becas-para-estancias-de-investigacion-en-inteligencia-ar-6d9a9023f63f4ac4PharmaRadar360en2026-09-15T12:42:00.000ZHeilbronn Ai Fellowship: Becas para estancias de investigación en Inteligencia Artificial en Alemaniahttps://www.pharmaradar360.com/article/canaccord-raises-definium-therapeutics-price-target-on-trial-results-823ad11d724e1346PharmaRadar360en2026-09-15T12:31:00.000ZCanaccord raises Definium Therapeutics price target on trial resultshttps://www.pharmaradar360.com/article/a-50-anos-de-la-noche-de-los-lapices-recuperar-la-historia-para-construir-nuevas-b16602b68dc469b8PharmaRadar360en2026-09-15T12:30:28.000ZA 50 años de la Noche de los Lápices: recuperar la historia para construir nuevas memoriashttps://www.pharmaradar360.com/article/survey-adults-with-multiple-or-complex-health-conditions-face-significant-challe-07e5b9e1d7bf6098PharmaRadar360en2026-09-15T12:30:00.000ZSurvey: Adults With Multiple or Complex Health Conditions Face Significant Challenges with Health Costs and Commonly Struggle to Access Carehttps://www.pharmaradar360.com/article/health-care-access-and-affordability-for-adults-with-multiple-or-complex-health-40f35f4aa2e21f66PharmaRadar360en2026-09-15T12:30:00.000ZHealth Care Access and Affordability for Adults with Multiple or Complex Health Conditions: A Snapshot of Patient Experienceshttps://www.pharmaradar360.com/article/abbvie-named-official-pharmaceutical-sponsor-of-the-pga-tour-and-2026-presidents-8c59bede56b31042PharmaRadar360en2026-09-15T12:30:00.000ZAbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaignhttps://www.pharmaradar360.com/article/vaccination-of-people-with-uncertain-or-incomplete-immunisation-2614a700ef581637PharmaRadar360en2026-09-15T12:24:37.000ZVaccination of people with uncertain or incomplete immunisationhttps://www.pharmaradar360.com/article/let-s-talk-with-sorrisi-in-rosa-10-anni-insieme-a936d1bccd7f37c2PharmaRadar360en2026-09-15T12:21:41.000ZLet’s talk with Sorrisi in Rosa: 10 anni insiemehttps://www.pharmaradar360.com/article/maia-biotechnology-announces-insider-share-purchases-by-board-member-and-ceo-ami-5517cde72350edd4PharmaRadar360en2026-09-15T12:21:00.000ZMAIA Biotechnology Announces Insider Share Purchases by Board Member and CEO Amid Positive Phase 3 and Phase 2 Data Updateshttps://www.pharmaradar360.com/article/la-aemps-habilita-una-nueva-aplicacion-para-presentar-telematicamente-la-declara-ced439fd208ddf21PharmaRadar360en2026-09-15T12:09:05.000ZLa AEMPS habilita una nueva aplicación para presentar telemáticamente la declaración responsable de actividades de fabricación y/o importación de productos de cuidado personalhttps://www.pharmaradar360.com/article/compass-pathways-just-answered-the-durability-question-now-comes-the-harder-prob-91b82d6d78659f27PharmaRadar360en2026-09-15T12:08:40.000ZCompass Pathways Just Answered the Durability Question. Now Comes the Harder Problem.https://www.pharmaradar360.com/article/nkgen-biotech-to-present-on-troculeucel-for-75400b55930fb023PharmaRadar360en2026-09-15T12:05:00.000ZNKGen Biotech to Present on Troculeucel forhttps://www.pharmaradar360.com/article/ori-biotech-announces-10-year-120m-partnership-to-advance-automated-manufacturin-a7a8016caf9792c3PharmaRadar360en2026-09-15T12:03:14.000ZOri Biotech Announces 10-year, $120M Partnership to Advance Automated Manufacturing for Commercial Cell Therapieshttps://www.pharmaradar360.com/article/lenders-take-over-big-biotech-projects-from-developers-amid-weak-market-0da1139c9a272cf0PharmaRadar360en2026-09-15T12:03:00.000ZLenders take over big biotech projects from developers amid weak markethttps://www.pharmaradar360.com/article/new-legend-biotech-nasdaq-legn-ceo-could-get-10m-a-year-in-stock-grants-83bafaed24e453a0PharmaRadar360en2026-09-15T12:01:05.000ZNew Legend Biotech (NASDAQ: LEGN) CEO could get $10M+ a year in stock grantshttps://www.pharmaradar360.com/article/why-ai-agents-invent-their-own-language-if-you-let-them-chat-9beb98df1bc5cd4bPharmaRadar360en2026-09-15T12:00:00.000ZWhy AI agents invent their own language if you let them chathttps://www.pharmaradar360.com/article/organika-gummies-foreign-site-not-listed-on-site-licence-a84ecb8691e76e80PharmaRadar360en2026-09-15T12:00:00.000ZOrganika® Gummies: Foreign site not listed on site licencehttps://www.pharmaradar360.com/article/the-target-product-profile-where-clinical-development-meets-commercial-reality-49a27a3d5b010a47PharmaRadar360en2026-09-15T12:00:00.000ZThe Target Product Profile: Where Clinical Development Meets Commercial Realityhttps://www.pharmaradar360.com/article/legend-biotech-appoints-ingrid-zhang-as-chief-executive-officer-1fc5f79e5180e8bePharmaRadar360en2026-09-15T12:00:00.000ZLegend Biotech Appoints Ingrid Zhang as Chief Executive Officerhttps://www.pharmaradar360.com/article/ori-biotech-announces-10-year-120m-partnership-to-advance-automated-manufacturin-7332490dba27ec05PharmaRadar360en2026-09-15T12:00:00.000ZOri Biotech Announces 10-year, $120M Partnership to Advance Automated Manufacturing for Commercial Cell Therapieshttps://www.pharmaradar360.com/article/allergan-aesthetics-to-advance-scientific-dialogue-on-skin-longevity-aging-biolo-22d33810a0bd348bPharmaRadar360en2026-09-15T12:00:00.000ZAllergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summithttps://www.pharmaradar360.com/article/una-leona-en-el-rectorado-vicky-granatto-graduada-ilustre-de-la-unlp-0995f5cfd227b39dPharmaRadar360en2026-09-15T11:56:12.000ZUna Leona en el Rectorado: Vicky Granatto, Graduada Ilustre de la UNLPhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-gets-breakthrough-therapy-designation-for-lung-cancer-drug-9a2411f77c5ff047PharmaRadar360en2026-09-15T11:50:33.000ZCSPC Pharmaceutical Gets Breakthrough Therapy Designation for Lung Cancer Drughttps://www.pharmaradar360.com/article/integrated-formulation-development-solubility-enhancement-modified-release-and-a-50a246e993c73d45PharmaRadar360en2026-09-15T11:42:59.000ZIntegrated Formulation Development: Solubility Enhancement, Modified Release and AI-Informed Drug Development - New Orleans, LAhttps://www.pharmaradar360.com/article/biovie-announces-topline-results-from-phase-2-address-lc-trial-evaluating-bezist-7ad61d619ea60776PharmaRadar360en2026-09-15T11:37:41.000ZBioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVIDhttps://www.pharmaradar360.com/article/thirlwall-inquiry-report-e6a6b02f944b9e08PharmaRadar360en2026-09-15T11:36:52.000ZThirlwall Inquiry reporthttps://www.pharmaradar360.com/article/gsk-doubles-down-on-china-biotech-paying-up-to-750-million-for-global-rights-to-7d22f9ea6a2666d5PharmaRadar360en2026-09-15T11:35:00.000ZGSK Doubles Down on China Biotech, Paying Up to $750 Million for Global Rights to Experimental Blood Cancer Therapyhttps://www.pharmaradar360.com/article/convegno-16-09-policlinico-kids-2-0-5666d4ba8d7e3d0fPharmaRadar360en2026-09-15T11:30:00.000Z#CONVEGNO [16.09] POLICLINICO KIDS 2.0https://www.pharmaradar360.com/article/an-estimated-17-20-million-u-s-adults-live-with-long-covid-biovie-reports-benefi-eae313323506dbb4PharmaRadar360en2026-09-15T11:30:00.000ZAn estimated 17–20 million U.S. adults live with Long COVID. BioVie reports benefits in hardest-hit patients.https://www.pharmaradar360.com/article/address-by-prof-mojisola-christianah-adeyeye-at-the-49th-annual-international-co-a2a7d60bb2244405PharmaRadar360en2026-09-15T11:23:36.000ZAddress by Prof. Mojisola Christianah Adeyeye at the 49th Annual International Conference of the Chemical Society of Nigeriahttps://www.pharmaradar360.com/article/gsk-bolsters-oncology-pipeline-with-750m-chimagen-tce-deal-826c82260bc41af2PharmaRadar360en2026-09-15T11:21:34.000ZGSK bolsters oncology pipeline with $750m Chimagen TCE dealhttps://www.pharmaradar360.com/article/ocular-therapeutixtm-announces-positive-pre-nda-meeting-with-u-s-fda-for-axpaxli-1b21a6d7086131d4PharmaRadar360en2026-09-15T11:16:54.000ZOcular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMDhttps://www.pharmaradar360.com/article/leading-biotech-selects-veeva-vault-crm-globally-10705eb8501f8596PharmaRadar360en2026-09-15T11:04:26.000ZLeading Biotech Selects Veeva Vault CRM Globallyhttps://www.pharmaradar360.com/article/leading-biotech-selects-veeva-vault-crm-globally-15d9a37158cd8455PharmaRadar360en2026-09-15T11:03:00.000ZLeading Biotech Selects Veeva Vault CRM Globallyhttps://www.pharmaradar360.com/article/ai-and-bioavailability-key-insights-from-quotient-sciences-at-cphi-milan-2026-pa-d647b90c22d390b2PharmaRadar360en2026-09-15T11:01:24.000ZAI and Bioavailability: Key Insights from Quotient Sciences at CPHI Milan 2026 (Part 1)https://www.pharmaradar360.com/article/dompe-u-s-pays-32-million-to-resolve-co-pay-foundation-kickback-allegations-foll-a18a9b45edf7a74dPharmaRadar360en2026-09-15T11:00:36.000ZDompé U.S. Pays $32 Million to Resolve Co-Pay Foundation Kickback Allegations Following Voluntary Self-Disclosurehttps://www.pharmaradar360.com/article/sacking-football-managers-does-not-improve-performance-study-finds-03c01ac7a2e8e41ePharmaRadar360en2026-09-15T11:00:32.000ZSacking football managers does not improve performance, study findshttps://www.pharmaradar360.com/article/a-study-performed-in-the-microbiology-department-of-vall-d-hebron-university-hos-a8d24f15864f0602PharmaRadar360en2026-09-15T11:00:00.000ZA Study Performed in the Microbiology Department of Vall d’Hebron University Hospital Shows High Agreement Between Manual Microscopy and Techcyte’s AI for Ova and Parasite Testing.https://www.pharmaradar360.com/article/ocular-therapeutixtm-announces-positive-pre-nda-meeting-with-u-s-fda-for-axpaxli-df8feae142024a4bPharmaRadar360en2026-09-15T11:00:00.000ZOcular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMDhttps://www.pharmaradar360.com/article/debut-engineers-new-biotech-ingredient-for-hyperpigmentation-bd42adb0c0606c65PharmaRadar360en2026-09-15T11:00:00.000ZDebut Engineers New Biotech Ingredient for Hyperpigmentationhttps://www.pharmaradar360.com/article/vera-kidney-drug-trutakna-shows-strong-final-results-in-phase-3-trial-df6628efe3598540PharmaRadar360en2026-09-15T10:53:50.000ZVera kidney drug Trutakna shows strong final results in Phase 3 trialhttps://www.pharmaradar360.com/article/meiji-group-to-showcase-japanese-quality-cmo-cdmo-services-and-a-global-manufact-e52ed07ed40f30acPharmaRadar360en2026-09-15T10:49:57.000ZMeiji Group to Showcase Japanese-Quality CMO/CDMO Services and a Global Manufacturing Network at CPHI Milan 2026https://www.pharmaradar360.com/article/stopping-gum-disease-before-it-starts-with-ai-9fb6b31196acfe4aPharmaRadar360en2026-09-15T10:46:07.000ZStopping gum disease before it starts with AIhttps://www.pharmaradar360.com/article/new-trustees-announced-as-cancer-research-uk-strengthens-research-and-governance-b0e6efe05865e793PharmaRadar360en2026-09-15T10:40:06.000ZNew Trustees announced as Cancer Research UK strengthens research and governance leadershiphttps://www.pharmaradar360.com/article/the-u-s-eradicated-this-flesh-eating-parasite-now-it-s-back-0a632145778feae0PharmaRadar360en2026-09-15T10:39:40.000ZThe U.S. Eradicated this flesh-eating parasite. Now it’s backhttps://www.pharmaradar360.com/article/vera-therapeutics-secures-strong-final-phase-3-data-for-kidney-drug-trutakna-36d5522ea33843a0PharmaRadar360en2026-09-15T10:30:00.000ZVera Therapeutics Secures Strong Final Phase 3 Data for Kidney Drug Trutaknahttps://www.pharmaradar360.com/article/how-tulane-is-spotting-startup-gems-inside-stacks-of-academic-research-1f9769591bca433cPharmaRadar360en2026-09-15T10:30:00.000ZHow Tulane is spotting startup gems inside stacks of academic researchhttps://www.pharmaradar360.com/article/eli-lilly-halts-early-stage-obesity-drug-development-d54510d85ed65bb4PharmaRadar360en2026-09-15T10:17:31.000ZEli Lilly halts early-stage obesity drug developmenthttps://www.pharmaradar360.com/article/widow-s-bay-triumphs-as-most-decorated-freshman-comedy-in-emmy-history-73c1fed3e66c3e88PharmaRadar360en2026-09-15T10:02:42.000ZWidow’s Bay triumphs as most decorated freshman comedy in Emmy historyhttps://www.pharmaradar360.com/article/veterans-and-doctors-urged-psychedelic-therapy-safety-standards-at-fda-hearing-w-fa6fb35f2fa9db3dPharmaRadar360en2026-09-15T10:00:03.000ZVeterans and Doctors Urged Psychedelic Therapy Safety Standards at FDA Hearing, with Comments Open Until October 5https://www.pharmaradar360.com/article/preorder-dci-s-new-2026-27-economic-report-on-pharmaceutical-wholesalers-and-spe-cf342a4bd277e1b1PharmaRadar360en2026-09-15T10:00:00.000ZPreorder DCI’s New 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributorshttps://www.pharmaradar360.com/article/european-radiology-abdomen-publishes-debut-articles-e0267cdf86aedfcaPharmaRadar360en2026-09-15T09:59:27.000ZEuropean Radiology Abdomen publishes debut articleshttps://www.pharmaradar360.com/article/florrax-pharmaceutical-updates-glp-core-tablet-product-information-in-dailymed-d-d44690b1b2608954PharmaRadar360en2026-09-15T09:55:11.000ZFlorrax Pharmaceutical Updates GLP CORE Tablet Product Information in DailyMed Databasehttps://www.pharmaradar360.com/article/exclusive-new-nih-research-center-on-vaccine-harms-takes-shape-9fff0ee16aaaf112PharmaRadar360en2026-09-15T09:55:00.000ZExclusive: New NIH research center on vaccine harms takes shapehttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-august-2026-1b10eeb5524e0803PharmaRadar360en2026-09-15T09:50:35.000ZUK Clinical Research Delivery key performance indicators: data to August 2026https://www.pharmaradar360.com/article/benemeat-warns-uk-eu-trade-deal-could-put-wider-biotech-ambitions-at-risk-fe6a683c0c2b29a5PharmaRadar360en2026-09-15T09:45:40.000ZBeneMeat warns UK–EU trade deal could put wider biotech ambitions at riskhttps://www.pharmaradar360.com/article/montana-s-giving-the-biotech-industry-sweeping-authority-to-sell-unapproved-drug-2190e459be361d76PharmaRadar360en2026-09-15T09:45:00.000ZMontana’s giving the biotech industry sweeping authority to sell unapproved drugshttps://www.pharmaradar360.com/article/lorraine-hill-joins-industry-leaders-in-conversation-on-gender-leadership-and-th-7d42b07921023b67PharmaRadar360en2026-09-15T09:30:00.000ZLorraine Hill joins industry leaders in conversation on gender, leadership and the future of manufacturinghttps://www.pharmaradar360.com/article/wclc-lung-cancer-news-from-biontech-akeso-and-roche-40c82f5f181ab638PharmaRadar360en2026-09-15T09:18:27.000ZWCLC: Lung cancer news from BioNTech, Akeso, and Rochehttps://www.pharmaradar360.com/article/what-fda-and-ema-now-accept-from-real-world-data-240492ab4fd2c3b1PharmaRadar360en2026-09-15T09:17:51.000ZWhat FDA and EMA now accept from real-world datahttps://www.pharmaradar360.com/article/chief-medical-officer-of-precision-for-medicine-line-between-phase-1-and-2-trial-5f656497ea653dbfPharmaRadar360en2026-09-15T09:15:00.000ZChief Medical Officer of Precision for Medicine: “Line between Phase 1 and 2 trials has vanished – Cancer drug development formula has changed”https://www.pharmaradar360.com/article/connecting-data-people-and-patients-how-ai-is-advancing-neuroscience-clinical-tr-fbb7dc892cca538aPharmaRadar360en2026-09-15T09:10:56.000ZConnecting Data, People, and Patients: How AI is Advancing Neuroscience Clinical Trialshttps://www.pharmaradar360.com/article/century-adds-biotech-veteran-as-cell-therapies-near-milestones-1287adafcb6350aePharmaRadar360en2026-09-15T09:10:32.000ZCentury Adds Biotech Veteran as Cell Therapies Near Milestoneshttps://www.pharmaradar360.com/article/don-t-get-caught-out-by-flu-this-winter-as-nhsggc-expands-vaccine-clinics-237642de4684a825PharmaRadar360en2026-09-15T09:08:31.000ZDon’t get caught out by flu this winter as NHSGGC expands vaccine clinicshttps://www.pharmaradar360.com/article/day-1-is-ai-in-biotech-real-growth-or-hype-24ea2945d48f00f2PharmaRadar360en2026-09-15T09:05:46.000ZDay 1 - Is AI in biotech real growth or hype?https://www.pharmaradar360.com/article/fda-regulation-and-the-dynamic-nature-of-ai-0c1651051d68903bPharmaRadar360en2026-09-15T09:00:00.000ZFDA Regulation and the Dynamic Nature of AIhttps://www.pharmaradar360.com/article/las-enfermedades-cardiovasculares-superan-al-cancer-y-se-posicionan-como-causa-p-63d69fa22573e6caPharmaRadar360en2026-09-15T09:00:00.000ZLas enfermedades cardiovasculares superan al cáncer y se posicionan como causa principal de muerte entre los adultos hispanos en EE. UU.https://www.pharmaradar360.com/article/cardiovascular-disease-tops-cancer-as-leading-cause-of-death-among-hispanic-adul-8f0dc26cd592f4b7PharmaRadar360en2026-09-15T09:00:00.000ZCardiovascular disease tops cancer as leading cause of death among Hispanic adults in U.S.https://www.pharmaradar360.com/article/what-is-driving-simcere-pharmaceutical-group-sehk-2096-higher-today-38c1d46a98971355PharmaRadar360en2026-09-15T08:56:46.000ZWhat Is Driving Simcere Pharmaceutical Group (SEHK:2096) Higher Today?https://www.pharmaradar360.com/article/china-s-biotech-ai-trade-finds-real-fuel-e3b1dea7cc9273dcPharmaRadar360en2026-09-15T08:56:24.000ZChina’s biotech AI trade finds real fuelhttps://www.pharmaradar360.com/article/regulatory-round-up-15-september-2026-a7c5aa202e8d1a2bPharmaRadar360en2026-09-15T08:55:35.000ZRegulatory round-up: 15 September 2026https://www.pharmaradar360.com/article/hanyang-precision-chairman-faces-breach-of-trust-embezzlement-allegations-7630c5cc0a515910PharmaRadar360en2026-09-15T08:51:23.000ZHanyang Precision Chairman Faces Breach of Trust, Embezzlement Allegationshttps://www.pharmaradar360.com/article/qasim-treated-by-specialists-with-all-the-rare-blood-available-across-the-countr-cf8bbd18e6915c1aPharmaRadar360en2026-09-15T08:42:54.000ZQasim treated by specialists with all the rare blood available across the countryhttps://www.pharmaradar360.com/article/bloodborne-virus-testing-in-prisons-and-other-places-of-detention-19658f88bc805354PharmaRadar360en2026-09-15T08:30:09.000ZBloodborne virus testing in prisons and other places of detentionhttps://www.pharmaradar360.com/article/leprosy-notifications-to-uk-national-surveillance-2001-to-2025-cbea52de19821e05PharmaRadar360en2026-09-15T08:30:08.000ZLeprosy notifications to UK national surveillance: 2001 to 2025https://www.pharmaradar360.com/article/fratture-costali-nuove-frontiere-chirurgiche-mininvasive-al-policlinico-di-milan-ae965af1975ddb4cPharmaRadar360en2026-09-15T08:28:00.000ZFratture costali: nuove frontiere chirurgiche mininvasive al Policlinico di Milanohttps://www.pharmaradar360.com/article/short-interest-in-chugai-pharmaceutical-co-ltd-unsponsored-adr-otcmkts-chgcy-exp-0ad45629e5c18f34PharmaRadar360en2026-09-15T08:24:41.000ZShort Interest in Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Expands By 90.3%https://www.pharmaradar360.com/article/data-science-unpicking-data-diversity-and-inclusive-research-design-e2ec926d17ea3e7cPharmaRadar360en2026-09-15T08:22:40.000ZData Science: unpicking data diversity and inclusive research designhttps://www.pharmaradar360.com/article/insilico-s-co-ceo-has-big-hopes-that-fibrosis-drug-can-reverse-aging-too-05298b94b951aeb6PharmaRadar360en2026-09-15T08:18:30.000ZInsilico’s Co-CEO Has Big Hopes That Fibrosis Drug Can Reverse Aging Toohttps://www.pharmaradar360.com/article/deutsche-bank-upgrades-astrazeneca-stock-rating-to-hold-on-trial-results-e24cf6dc3282e01aPharmaRadar360en2026-09-15T08:08:00.000ZDeutsche Bank upgrades AstraZeneca stock rating to hold on trial resultshttps://www.pharmaradar360.com/article/pharmaceutical-manufacturing-company-abec-opens-north-carolina-facility-35b14667e72d9b33PharmaRadar360en2026-09-15T08:06:14.000ZPharmaceutical manufacturing company ABEC opens North Carolina facilityhttps://www.pharmaradar360.com/article/bbsrc-publishes-refreshed-edi-action-plan-for-2026-to-2028-5b9f44f6886b921cPharmaRadar360en2026-09-15T08:00:33.000ZBBSRC publishes refreshed EDI action plan for 2026 to 2028https://www.pharmaradar360.com/article/passaparola-28-09-02-10-h-open-week-malattie-cardiovascolari-84f3f324009bddd2PharmaRadar360en2026-09-15T08:00:00.000Z#PASSAPAROLA. [28.09 - 02.10] (H) OPEN WEEK Malattie Cardiovascolarihttps://www.pharmaradar360.com/article/every-electron-counts-most-detailed-protein-structure-to-date-revealed-05e3072f40e0c0d6PharmaRadar360en2026-09-15T08:00:00.000ZEvery electron counts: most detailed protein structure to date revealedhttps://www.pharmaradar360.com/article/yprime-guide-supply-management-critical-to-irt-trial-success-for-biotech-sponsor-ff618748e3e73b3ePharmaRadar360en2026-09-15T07:58:40.000ZYPrime Guide: Supply Management Critical to IRT Trial Success for Biotech Sponsorshttps://www.pharmaradar360.com/article/definium-s-dt120-odt-meets-primary-endpoint-in-phase-3-gad-study-ffdc87d33d747ddaPharmaRadar360en2026-09-15T07:58:40.000ZDefinium’s DT120 ODT Meets Primary Endpoint in Phase 3 GAD Studyhttps://www.pharmaradar360.com/article/the-fda-just-handed-psychedelic-drug-sponsors-a-framework-now-the-hard-part-star-0df868a4710c99b2PharmaRadar360en2026-09-15T07:58:40.000ZThe FDA Just Handed Psychedelic Drug Sponsors a Framework. Now the Hard Part Starts.https://www.pharmaradar360.com/article/us-company-uses-biotech-to-develop-more-effective-biological-pesticides-584a7468194ba384PharmaRadar360en2026-09-15T07:53:05.000ZUS company uses biotech to develop more effective biological pesticideshttps://www.pharmaradar360.com/article/esr-mourns-the-passing-of-prof-filipe-caseiro-alves-30d53a422912c304PharmaRadar360en2026-09-15T07:44:45.000ZESR mourns the passing of Prof. Filipe Caseiro Alveshttps://www.pharmaradar360.com/article/biohaven-advanced-bhv-7000-to-pivotal-trials-without-answering-a-question-the-fd-8ef994cf536ab4e7PharmaRadar360en2026-09-15T07:38:40.000ZBiohaven Advanced BHV-7000 to Pivotal Trials Without Answering a Question the FDA Requires Every Sponsor to Answerhttps://www.pharmaradar360.com/article/after-ras-inhibitors-what-comes-next-in-pancreatic-cancer-ecf1adfe3a0130a8PharmaRadar360en2026-09-15T07:31:00.000ZAfter RAS inhibitors: what comes next in pancreatic cancer?https://www.pharmaradar360.com/article/hannah-benisty-and-maximilian-stammnitz-join-ar-i-crg-mountain-genomics-talent-p-4c62b23e8d169932PharmaRadar360en2026-09-15T07:30:47.000ZHannah Benisty and Maximilian Stammnitz join AR+I–CRG Mountain Genomics Talent Programmehttps://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-nutx-8-iova-7-atrc-cnc-con-4690179e4c18e9cdPharmaRadar360en2026-09-15T07:25:00.000ZBiotech Stocks At 52-Week Highs - NUTX +8%, IOVA +7%, ATRC, CNC, CONhttps://www.pharmaradar360.com/article/biotech-stocks-facing-fda-decision-in-october-2026-32d5468f90b77d0bPharmaRadar360en2026-09-15T07:20:00.000ZBiotech Stocks Facing FDA Decision In October 2026https://www.pharmaradar360.com/article/genfit-plans-phase-2-liver-failure-trial-after-acquiring-immunomodulator-from-in-a5b612c6084d9b58PharmaRadar360en2026-09-15T07:02:29.000ZGenfit plans Phase 2 liver failure trial after acquiring immunomodulator from Inotremhttps://www.pharmaradar360.com/article/unmc-created-digital-platform-nets-recognition-nih-grant-d95c7fa1ac47495bPharmaRadar360en2026-09-15T07:00:00.000ZUNMC-created digital platform nets recognition, NIH granthttps://www.pharmaradar360.com/article/eur-and-erasmus-mc-once-again-achieved-nearly-100-open-access-in-2025-29ceeb281f399463PharmaRadar360en2026-09-15T07:00:00.000ZEUR and Erasmus MC once again achieved nearly 100% Open Access in 2025https://www.pharmaradar360.com/article/u-s-news-world-report-names-uc-davis-children-s-hospital-among-best-children-s-h-81eff130777decf6PharmaRadar360en2026-09-15T07:00:00.000ZU.S. News & World Report names UC Davis Children’s Hospital among Best Children’s Hospitals for 2026-2027https://www.pharmaradar360.com/article/northern-nevada-based-cancer-care-specialists-joins-uc-davis-cancer-care-network-7f2acb3d8d3957d1PharmaRadar360en2026-09-15T07:00:00.000ZNorthern Nevada-based Cancer Care Specialists joins UC Davis Cancer Care Network as affiliatehttps://www.pharmaradar360.com/article/as-wildfire-smoke-exposure-grows-uc-davis-researchers-seek-answers-92f9b79dafc9784fPharmaRadar360en2026-09-15T07:00:00.000ZAs wildfire smoke exposure grows, UC Davis researchers seek answershttps://www.pharmaradar360.com/article/partnership-creates-pathway-from-clarkson-college-to-unmc-pharmacy-programs-63ab3960072b2c50PharmaRadar360en2026-09-15T06:58:00.000ZPartnership creates pathway from Clarkson College to UNMC pharmacy programshttps://www.pharmaradar360.com/article/huons-teams-with-3-biotechs-on-mrna-adc-peptide-drug-projects-e922bd96adfa7ffaPharmaRadar360en2026-09-15T06:56:41.000ZHuons teams with 3 biotechs on mRNA, ADC, peptide drug projectshttps://www.pharmaradar360.com/article/9-22-nhk-e-cdb01965a93c2f77PharmaRadar360en2026-09-15T06:56:35.000Z【9/22放送予定】NHK Eテレ「きょうの健康」に皮膚科 科長 浅野 善英教授が出演しますhttps://www.pharmaradar360.com/article/frazier-life-sciences-adds-1-1bn-to-public-biotech-fund-taking-total-commitments-ff6f44cd37484361PharmaRadar360en2026-09-15T06:56:07.000ZFrazier Life Sciences adds $1.1bn to public biotech fund, taking total commitments to $2.8bnhttps://www.pharmaradar360.com/article/forsberg-event-captured-majesty-of-whooping-cranes-d2c7373c7604ca90PharmaRadar360en2026-09-15T06:56:00.000ZForsberg event captured majesty of whooping craneshttps://www.pharmaradar360.com/article/why-the-eu-biotech-act-must-deliver-practical-improvements-for-clinical-trials-i-cd6fa0b28c6148cePharmaRadar360en2026-09-15T06:55:29.000ZWhy the EU Biotech Act must deliver practical improvements for clinical trials in Europehttps://www.pharmaradar360.com/article/durham-outpatient-center-circle-drive-to-update-striping-c98d347bad7d3824PharmaRadar360en2026-09-15T06:50:00.000ZDurham Outpatient Center circle drive to update stripinghttps://www.pharmaradar360.com/article/sionna-to-test-sion-451-and-sion-2222-combo-in-cf-phase-2a-trial-502cb66a8d1bb08aPharmaRadar360en2026-09-15T06:48:40.000ZSionna to Test SION-451 and SION-2222 Combo in CF Phase 2a Trialhttps://www.pharmaradar360.com/article/evonik-invests-80-million-to-expand-biotech-production-in-slovakia-e5631308d237f1b5PharmaRadar360en2026-09-15T06:45:46.000ZEvonik Invests €80 Million to Expand Biotech Production in Slovakiahttps://www.pharmaradar360.com/article/keeps-biopharma-s-idetrexed-wins-korean-phase-2-ind-approval-c048c54abe2e3304PharmaRadar360en2026-09-15T06:21:35.000ZKeeps Biopharma’s Idetrexed wins Korean phase 2 IND approvalhttps://www.pharmaradar360.com/article/pharmaceutical-firm-boryung-to-split-off-sales-marketing-divisions-ef1110c02ba6eaa5PharmaRadar360en2026-09-15T05:49:59.000ZPharmaceutical firm Boryung to split-off sales, marketing divisionshttps://www.pharmaradar360.com/article/purity-with-purpose-clariant-health-care-raises-the-bar-for-pharmaceutical-excip-ed1ca819e43d20f0PharmaRadar360en2026-09-15T05:28:20.000ZPurity with purpose: Clariant Health Care raises the bar for pharmaceutical excipientshttps://www.pharmaradar360.com/article/gemeinsam-fur-ein-gesundes-uniklinikum-8e963b027cfbb561PharmaRadar360en2026-09-15T05:00:00.000ZGemeinsam für ein gesundes Uniklinikumhttps://www.pharmaradar360.com/article/india-could-get-its-first-indigenous-dengue-vaccine-by-2027-icmr-dg-reveals-time-544de43e0a215d6ePharmaRadar360en2026-09-15T04:55:00.000ZIndia Could Get Its First Indigenous Dengue Vaccine by 2027: ICMR DG Reveals Timelinehttps://www.pharmaradar360.com/article/etfs-investing-in-mochida-pharmaceutical-co-ltd-stocks-c9e7c6384cd77f6bPharmaRadar360en2026-09-15T04:13:46.000ZETFs Investing in Mochida Pharmaceutical Co., Ltd. Stockshttps://www.pharmaradar360.com/article/esophageal-ph-monitoring-capsule-recall-medtronic-and-given-imaging-remove-esoph-d9cf1ce94eb38542PharmaRadar360en2026-09-15T04:00:00.000ZEsophageal pH Monitoring Capsule Recall: Medtronic and Given Imaging Remove Esophageal pH Monitoring Capsule Delivery Devicehttps://www.pharmaradar360.com/article/nearly-10-000-patients-reveal-what-works-best-for-knee-arthritis-pain-relief-efa56f58b8e874fbPharmaRadar360en2026-09-15T03:57:43.000ZNearly 10,000 patients reveal what works best for knee arthritis pain reliefhttps://www.pharmaradar360.com/article/tiny-cell-antennas-may-help-explain-why-some-babies-are-born-with-heart-defects-1e6857f6c530acbdPharmaRadar360en2026-09-15T03:20:52.000ZTiny cell “antennas” may help explain why some babies are born with heart defectshttps://www.pharmaradar360.com/article/ai-native-biotech-yudao-bio-raises-30m-series-c-76640c7b47244685PharmaRadar360en2026-09-15T03:07:32.000ZAI-native biotech Yudao Bio raises $30M Series Chttps://www.pharmaradar360.com/article/plague-was-killing-entire-families-thousands-of-years-before-the-black-death-d0f81adc1c6595acPharmaRadar360en2026-09-15T02:54:45.000ZPlague was killing entire families thousands of years before the Black Deathhttps://www.pharmaradar360.com/article/amgen-vs-vertex-pharmaceuticals-value-stability-vs-high-growth-biotech-investmen-cf23a82612abdb43PharmaRadar360en2026-09-15T02:47:51.000ZAmgen vs. Vertex Pharmaceuticals: Value Stability vs. High-Growth Biotech Investment Playshttps://www.pharmaradar360.com/article/2027-5a1abac55f9bda0ePharmaRadar360en2026-09-15T02:36:41.000Z東北大学ジャパンバイオデザインプログラム 2027年度フェロー募集のお知らせhttps://www.pharmaradar360.com/article/flinders-nuclear-courses-to-power-south-australia-s-future-aukus-workforce-b519f116eb423145PharmaRadar360en2026-09-15T02:33:42.000ZFlinders’ nuclear courses to power South Australia’s future AUKUS workforcehttps://www.pharmaradar360.com/article/5-best-biotech-stocks-for-2026-and-how-to-invest-95a8df16f2907324PharmaRadar360en2026-09-15T01:36:00.000Z5 Best Biotech Stocks for 2026 and How to Investhttps://www.pharmaradar360.com/article/test-seoul-biotech-startups-enter-boston-pipeline-through-labcentral-950b2083d7c96cafPharmaRadar360en2026-09-15T01:30:47.000Ztest Seoul biotech startups enter Boston pipeline through LabCentralhttps://www.pharmaradar360.com/article/navigating-biopharma-complexity-why-long-term-partnerships-matter-39b1115d3c1f4806PharmaRadar360en2026-09-15T01:21:30.000ZNavigating Biopharma Complexity: Why Long-Term Partnerships Matterhttps://www.pharmaradar360.com/article/propriedade-intelectual-e-eficiencia-regulatoria-como-motores-do-bem-estar-regio-47eb0fde5a9a0cb3PharmaRadar360en2026-09-15T01:16:21.000ZPropriedade intelectual e eficiência regulatória como motores do bem-estar regionalhttps://www.pharmaradar360.com/article/cancer-detection-biotech-lodges-patent-suit-against-rival-97957de1513c39f1PharmaRadar360en2026-09-15T01:11:00.000ZCancer Detection Biotech Lodges Patent Suit Against Rivalhttps://www.pharmaradar360.com/article/intellectual-property-and-regulatory-efficiency-as-drivers-of-regional-well-bein-0e91412e61ed6c95PharmaRadar360en2026-09-15T01:04:18.000ZIntellectual property and regulatory efficiency as drivers of regional well-beinghttps://www.pharmaradar360.com/article/report-from-the-fda-s-hearing-on-psychedelic-drugs-9a4b8269165dba38PharmaRadar360en2026-09-15T01:03:14.000ZReport from the FDA’s hearing on psychedelic drugshttps://www.pharmaradar360.com/article/bsr-sdic-biotech-seek-cooperation-on-ethanol-biofuels-96d7ccba31ab201dPharmaRadar360en2026-09-15T00:58:01.000ZBSR, SDIC Biotech seek cooperation on ethanol, biofuelshttps://www.pharmaradar360.com/article/swiss-biotech-giant-lonza-breaks-ground-on-major-bend-expansion-6a4e618ea7fbf639PharmaRadar360en2026-09-15T00:55:11.000ZSwiss biotech giant Lonza breaks ground on major Bend expansionhttps://www.pharmaradar360.com/article/propiedad-intelectual-y-eficiencia-regulatoria-como-motores-del-bienestar-region-636ab545130e30a3PharmaRadar360en2026-09-15T00:13:30.000ZPropiedad intelectual y eficiencia regulatoria como motores del bienestar regionalhttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-8a0e637c0b3e4dbePharmaRadar360en2026-09-15T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-6f021ed602180448PharmaRadar360en2026-09-15T00:00:00.000ZNovo Nordisk filed Form 6-Khttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-4bd9ab41996e78abPharmaRadar360en2026-09-15T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/engineering-botulinum-neurotoxin-into-anti-cancer-agents-a961c38b9f672a2aPharmaRadar360en2026-09-15T00:00:00.000ZEngineering botulinum neurotoxin into anti-cancer agentshttps://www.pharmaradar360.com/article/a-hierarchical-genomic-framework-associated-with-response-to-braf-directed-thera-28c3a45aa18ad1e5PharmaRadar360en2026-09-15T00:00:00.000ZA hierarchical genomic framework associated with response to BRAF-directed therapy across solid tumorshttps://www.pharmaradar360.com/article/intracranial-recordings-in-humans-reveal-differential-contributions-of-medial-an-727fada75d1c43ecPharmaRadar360en2026-09-15T00:00:00.000ZIntracranial recordings in humans reveal differential contributions of medial and lateral orbitofrontal cortex to approach–avoidance decision-makinghttps://www.pharmaradar360.com/article/broadly-neutralizing-antibodies-in-adult-males-living-with-hiv-undergoing-analyt-10c7cdd6ae46e688PharmaRadar360en2026-09-15T00:00:00.000ZBroadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trialhttps://www.pharmaradar360.com/article/beyond-the-breakthrough-for-ras-driven-cancers-fb8906a37f894648PharmaRadar360en2026-09-15T00:00:00.000ZBeyond the breakthrough for RAS-driven cancershttps://www.pharmaradar360.com/article/on-premise-medical-ai-agents-for-reliable-clinical-decision-making-5faadfdcab1519abPharmaRadar360en2026-09-15T00:00:00.000ZOn-premise medical AI agents for reliable clinical decision-makinghttps://www.pharmaradar360.com/article/oral-kras-g12d-inhibitor-gfh375-for-previously-treated-advanced-solid-tumors-wit-f3764900861d3f6ePharmaRadar360en2026-09-15T00:00:00.000ZOral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRAS G12D mutations: a phase 1 trialhttps://www.pharmaradar360.com/article/a-versatile-nanopore-identifies-four-classes-of-analytes-simultaneously-1d1ed26f07ad5c33PharmaRadar360en2026-09-15T00:00:00.000ZA versatile nanopore identifies four classes of analytes simultaneouslyhttps://www.pharmaradar360.com/article/ensuring-safety-and-accountability-in-china-s-biomedical-translation-system-24d508374c9320bbPharmaRadar360en2026-09-15T00:00:00.000ZEnsuring safety and accountability in China’s biomedical translation systemhttps://www.pharmaradar360.com/article/quality-control-of-glycogen-through-direct-ubiquitylation-by-rnf213-a40fb56dcdf3e131PharmaRadar360en2026-09-15T00:00:00.000ZQuality control of glycogen through direct ubiquitylation by RNF213https://www.pharmaradar360.com/article/author-correction-erythropoietin-receptor-on-cdc1s-dictates-immune-tolerance-aef989b5d5a1aab5PharmaRadar360en2026-09-15T00:00:00.000ZAuthor Correction: Erythropoietin receptor on cDC1s dictates immune tolerancehttps://www.pharmaradar360.com/article/why-nepal-floods-resulted-in-a-disaster-even-after-satellites-spotted-danger-6e82321e44a67096PharmaRadar360en2026-09-15T00:00:00.000ZWhy Nepal floods resulted in a disaster even after satellites spotted dangerhttps://www.pharmaradar360.com/article/why-the-nih-must-resist-the-metrics-trap-087943e1f4f738fbPharmaRadar360en2026-09-15T00:00:00.000ZWhy the NIH must resist the metrics traphttps://www.pharmaradar360.com/article/make-ai-traceable-before-it-shapes-global-climate-assessments-095e20bfe46c840cPharmaRadar360en2026-09-15T00:00:00.000ZMake AI traceable before it shapes global climate assessmentshttps://www.pharmaradar360.com/article/a-wake-up-call-diversify-global-research-funding-ac1e73ac7378f0acPharmaRadar360en2026-09-15T00:00:00.000ZA wake-up call: diversify global research fundinghttps://www.pharmaradar360.com/article/global-inequality-panel-is-a-chance-for-research-to-change-lives-68c3c3d680dcc246PharmaRadar360en2026-09-15T00:00:00.000ZGlobal inequality panel is a chance for research to change liveshttps://www.pharmaradar360.com/article/cities-and-countryside-are-intimately-linked-green-initiatives-must-recognize-th-f1fff31fe0760c03PharmaRadar360en2026-09-15T00:00:00.000ZCities and countryside are intimately linked — green initiatives must recognize thathttps://www.pharmaradar360.com/article/underground-hydrogen-could-spur-a-green-energy-revolution-if-companies-can-find-afaa3b23ce54753fPharmaRadar360en2026-09-15T00:00:00.000ZUnderground hydrogen could spur a green-energy revolution — if companies can find ithttps://www.pharmaradar360.com/article/crispr-crops-are-coming-to-europe-why-bolder-would-be-better-ff5c4493589485ddPharmaRadar360en2026-09-15T00:00:00.000ZCRISPR crops are coming to Europe — why bolder would be betterhttps://www.pharmaradar360.com/article/the-geometric-genius-of-rene-descartes-3949e7d17149db6cPharmaRadar360en2026-09-15T00:00:00.000ZThe geometric genius of René Descarteshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-80d5d3a67b0297dbPharmaRadar360en2026-09-15T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-75d6112bdcc05545PharmaRadar360en2026-09-15T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-71349bc9aa23e66bPharmaRadar360en2026-09-15T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-f2d813da61b080d3PharmaRadar360en2026-09-15T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-ab461ddce374a3afPharmaRadar360en2026-09-15T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-1ad6db83fca4d7aaPharmaRadar360en2026-09-15T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-f9efb9dd7fc1c8c4PharmaRadar360en2026-09-15T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-0cdd221cc37b19c3PharmaRadar360en2026-09-15T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-428e762851cd6fccPharmaRadar360en2026-09-15T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-1fb384b97542e0b3PharmaRadar360en2026-09-15T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-2769639a5b254ae5PharmaRadar360en2026-09-15T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-8f7ab7a97b96755ePharmaRadar360en2026-09-15T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-916c96d360b965dbPharmaRadar360en2026-09-15T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-024bdb231402bb6fPharmaRadar360en2026-09-15T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/world-trade-center-health-program-petition-048a-peripheral-artery-disease-findin-f6d3e799437ce4e2PharmaRadar360en2026-09-15T00:00:00.000ZWorld Trade Center Health Program; Petition 048a-Peripheral Artery Disease; Finding of Insufficient Evidencehttps://www.pharmaradar360.com/article/world-trade-center-health-program-petitions-048-and-051a-stroke-finding-of-insuf-75f442dab1d68f6ePharmaRadar360en2026-09-15T00:00:00.000ZWorld Trade Center Health Program; Petitions 048 and 051a-Stroke; Finding of Insufficient Evidencehttps://www.pharmaradar360.com/article/prospective-grant-of-an-exclusive-patent-license-development-and-commercializati-f2565eb7e1fb798ePharmaRadar360en2026-09-15T00:00:00.000ZProspective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of HPV 16 E6-Expressing Cancershttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-0626beb47d66f9d1PharmaRadar360en2026-09-15T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-b8a95ad8905e26c2PharmaRadar360en2026-09-15T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/proposed-information-collection-activity-multistate-financial-institution-data-m-3021d4ff81f706b9PharmaRadar360en2026-09-15T00:00:00.000ZProposed Information Collection Activity; Multistate Financial Institution Data Match With Federally Assisted State Transmitted Levyhttps://www.pharmaradar360.com/article/national-cancer-institute-notice-of-closed-meeting-421eb7f1bbe8c043PharmaRadar360en2026-09-15T00:00:00.000ZNational Cancer Institute; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/statistical-considerations-for-the-design-of-rare-disease-clinical-investigation-ebf052b141198824PharmaRadar360en2026-09-15T00:00:00.000ZStatistical Considerations for the Design of Rare Disease Clinical Investigations; Establishment of a Public Docket; Request for Information and Commentshttps://www.pharmaradar360.com/article/vill-knacka-hjartats-genetiska-kod-9a93a6184f8cdb67PharmaRadar360en2026-09-15T00:00:00.000ZVill knäcka hjärtats genetiska kodhttps://www.pharmaradar360.com/article/till-minne-av-jan-ake-gustafsson-1943-2026-157d552849da7002PharmaRadar360en2026-09-15T00:00:00.000ZTill minne av Jan-Åke Gustafsson (1943-2026)https://www.pharmaradar360.com/article/ny-metod-minskade-aterfall-vid-formaksflimmer-15d874ef8dcb95f0PharmaRadar360en2026-09-15T00:00:00.000ZNy metod minskade återfall vid förmaksflimmerhttps://www.pharmaradar360.com/article/ny-avhandling-undersoker-hur-dna-reparation-och-amnesomsattning-paverkar-immunsv-a92b2f175e0d7a03PharmaRadar360en2026-09-15T00:00:00.000ZNy avhandling undersöker hur DNA-reparation och ämnesomsättning påverkar immunsvarethttps://www.pharmaradar360.com/article/ny-avhandling-kartlagger-hjartskada-vid-svar-sepsis-14e2c43b092c5994PharmaRadar360en2026-09-15T00:00:00.000ZNy avhandling kartlägger hjärtskada vid svår sepsishttps://www.pharmaradar360.com/article/johan-askling-far-stipendium-for-patientnara-forskning-a73dfde5d21fffa7PharmaRadar360en2026-09-15T00:00:00.000ZJohan Askling får stipendium för patientnära forskninghttps://www.pharmaradar360.com/article/hjarnans-blodflode-kopplas-till-trotthet-efter-covid-f64ebc22e61c93a4PharmaRadar360en2026-09-15T00:00:00.000ZHjärnans blodflöde kopplas till trötthet efter covidhttps://www.pharmaradar360.com/article/cleveland-clinic-children-s-named-among-the-nation-s-best-children-s-hospitals-882b1ccab9ab1c35PharmaRadar360en2026-09-15T00:00:00.000ZCleveland Clinic Children's Named Among the Nation’s Best Children’s Hospitalshttps://www.pharmaradar360.com/article/jama-8ec86eab73be8490PharmaRadar360en2026-09-15T00:00:00.000ZJAMAhttps://www.pharmaradar360.com/article/audio-highlights-august-21-2026-cdf70b6bc9b1aa3fPharmaRadar360en2026-09-15T00:00:00.000ZAudio Highlights August 21, 2026https://www.pharmaradar360.com/article/gestational-hypertension-has-increased-affecting-1-in-10-pregnancies-cd46702af2461f9dPharmaRadar360en2026-09-15T00:00:00.000ZGestational Hypertension Has Increased, Affecting 1 in 10 Pregnancieshttps://www.pharmaradar360.com/article/fda-approves-first-freeze-dried-plasma-product-in-the-us-91551b9c452b7fcaPharmaRadar360en2026-09-15T00:00:00.000ZFDA Approves First Freeze-Dried Plasma Product in the UShttps://www.pharmaradar360.com/article/glp-1-drugs-linked-to-lower-fracture-risk-in-people-with-type-2-diabetes-ac0db8b55f56cfc2PharmaRadar360en2026-09-15T00:00:00.000ZGLP-1 Drugs Linked to Lower Fracture Risk in People With Type 2 Diabeteshttps://www.pharmaradar360.com/article/fda-approves-first-acetaminophen-and-naproxen-sodium-combination-drug-23f6a2ff6b0ab515PharmaRadar360en2026-09-15T00:00:00.000ZFDA Approves First Acetaminophen and Naproxen Sodium Combination Drughttps://www.pharmaradar360.com/article/are-e-scooters-more-dangerous-than-motorcycles-and-bicycles-9309e6f9174b333cPharmaRadar360en2026-09-15T00:00:00.000ZAre E-Scooters More Dangerous Than Motorcycles and Bicycles?https://www.pharmaradar360.com/article/aap-acog-speak-out-against-executive-order-fd97f969adb97da8PharmaRadar360en2026-09-15T00:00:00.000ZAAP, ACOG Speak Out Against Executive Orderhttps://www.pharmaradar360.com/article/the-organoid-era-0d1d74c17c3dfac6PharmaRadar360en2026-09-15T00:00:00.000ZThe Organoid Erahttps://www.pharmaradar360.com/article/cyclospora-outbreak-reveals-gaps-in-foodborne-disease-surveillance-9c1923e37ef042aaPharmaRadar360en2026-09-15T00:00:00.000ZCyclospora Outbreak Reveals Gaps in Foodborne Disease Surveillancehttps://www.pharmaradar360.com/article/is-life-worth-saving-87e8ab3b696abb6dPharmaRadar360en2026-09-15T00:00:00.000ZIs Life Worth Saving?https://www.pharmaradar360.com/article/glp-1s-from-gut-hormone-discovery-to-a-public-health-revolution-dc098d40197dcc75PharmaRadar360en2026-09-15T00:00:00.000ZGLP-1s—From Gut Hormone Discovery to a Public Health Revolutionhttps://www.pharmaradar360.com/article/the-original-yes-66773534912b3190PharmaRadar360en2026-09-15T00:00:00.000ZThe Original “Yes”https://www.pharmaradar360.com/article/unspoken-7afae036d0f0f51fPharmaRadar360en2026-09-15T00:00:00.000Zunspokenhttps://www.pharmaradar360.com/article/healing-through-catharsis-in-poetry-c1c641915b1e651ePharmaRadar360en2026-09-15T00:00:00.000ZHealing Through Catharsis in Poetryhttps://www.pharmaradar360.com/article/time-to-inpatient-management-for-boarding-emergency-department-patients-4c8a954c5150c6afPharmaRadar360en2026-09-15T00:00:00.000ZTime to Inpatient Management for Boarding Emergency Department Patientshttps://www.pharmaradar360.com/article/will-autonomous-ai-exceed-ai-aided-physicians-as-the-best-medical-care-f1019c797800d26ePharmaRadar360en2026-09-15T00:00:00.000ZWill Autonomous AI Exceed AI-Aided Physicians as the Best Medical Care?https://www.pharmaradar360.com/article/accelerating-workforce-well-being-2af5f79a317fd31bPharmaRadar360en2026-09-15T00:00:00.000ZAccelerating Workforce Well-Beinghttps://www.pharmaradar360.com/article/accelerating-workforce-well-being-reply-3b9c300a95d19024PharmaRadar360en2026-09-15T00:00:00.000ZAccelerating Workforce Well-Being—Replyhttps://www.pharmaradar360.com/article/updated-guidance-for-author-use-of-ai-in-medical-publication-bb959e0d57595750PharmaRadar360en2026-09-15T00:00:00.000ZUpdated Guidance for Author Use of AI in Medical Publicationhttps://www.pharmaradar360.com/article/a-new-era-in-the-treatment-of-metabolic-dysfunction-associated-steatotic-liver-d-bc2991c82cd3907fPharmaRadar360en2026-09-15T00:00:00.000ZA new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challengeshttps://www.pharmaradar360.com/article/pharmacokinetics-and-safety-comparison-of-cycloserine-capsules-and-their-generic-b2e30b35cb0877d2PharmaRadar360en2026-09-15T00:00:00.000ZPharmacokinetics and safety comparison of cycloserine capsules and their generic counterpart: a randomized, open-label, two-period, two-sequence, single-dose crossover bioequivalence study in healthy Chinese subjectshttps://www.pharmaradar360.com/article/clinical-outcomes-and-treatment-adherence-among-patients-receiving-care-for-sexu-43adcc1d39fbcea3PharmaRadar360en2026-09-15T00:00:00.000ZClinical Outcomes and Treatment Adherence among Patients Receiving Care for Sexually Transmitted Infections in Primary Health Care Centres in Southern Nigeriahttps://www.pharmaradar360.com/article/adolescent-centered-cannabis-messaging-in-clinical-settings-preliminary-qualitat-b8d6c3a5e7c2239fPharmaRadar360en2026-09-15T00:00:00.000ZAdolescent-Centered Cannabis Messaging in Clinical Settings: Preliminary Qualitative Insights From Adolescents for Clinicianshttps://www.pharmaradar360.com/article/delays-in-malignant-neck-mass-diagnosis-missed-opportunities-in-clinical-decisio-9b3c51828bc44be9PharmaRadar360en2026-09-15T00:00:00.000ZDelays in Malignant Neck Mass Diagnosis: Missed Opportunities in Clinical Decision-Makinghttps://www.pharmaradar360.com/article/diagnostic-performance-of-clinical-examination-for-detecting-knee-effusion-impac-faed480839f597f4PharmaRadar360en2026-09-15T00:00:00.000ZDiagnostic Performance of Clinical Examination for Detecting Knee Effusion: Impact of Obesity and Periarticular Adiposityhttps://www.pharmaradar360.com/article/harnessing-bioinformatics-to-decode-drug-resistance-and-guide-vaccine-design-in-6de558308b79a690PharmaRadar360en2026-09-15T00:00:00.000ZHarnessing Bioinformatics to Decode Drug Resistance and Guide Vaccine Design in Mycobacterium tuberculosis<i></i>https://www.pharmaradar360.com/article/afp-commissioner-urges-conversation-about-link-between-australians-level-of-illi-928113742fc8c7bcPharmaRadar360en2026-09-15T00:00:00.000ZAFP commissioner urges ‘conversation’ about link between Australians’ level of illicit drug use and organised crimehttps://www.pharmaradar360.com/article/clinical-signs-the-forgotten-art-part-3-ten-more-bedside-signs-every-clinician-s-dad7c35192128594PharmaRadar360en2026-09-15T00:00:00.000ZClinical Signs – The Forgotten Art (Part 3): Ten More Bedside Signs Every Clinician Should Masterhttps://www.pharmaradar360.com/article/real-world-computer-aided-detection-for-adenoma-detection-promising-but-context-5c32ac5fe4accd6fPharmaRadar360en2026-09-15T00:00:00.000ZReal-world computer-aided detection for adenoma detection: promising but context-dependenthttps://www.pharmaradar360.com/article/correlations-of-the-expression-of-akap95-cx43-cpsf5-6-scffbxl2-and-scffbxo31-in-457d4f522a00c9edPharmaRadar360en2026-09-15T00:00:00.000ZCorrelations of the expression of AKAP95, Cx43, CPSF5/6, SCFFBXL2 and SCFFBXO31 in lung cancer tissueshttps://www.pharmaradar360.com/article/clinical-decision-support-for-precolonoscopy-cancer-triage-a-rule-out-oriented-m-4254b4df21b60a7bPharmaRadar360en2026-09-15T00:00:00.000ZClinical decision support for precolonoscopy cancer triage: A rule-out-oriented machine learning model for colorectal cancer riskhttps://www.pharmaradar360.com/article/perceptions-of-nursing-undergraduates-regarding-their-clinical-placements-a-qual-25bbee34a69cbf71PharmaRadar360en2026-09-15T00:00:00.000ZPerceptions of Nursing Undergraduates Regarding Their Clinical Placements: A Qualitative Interpretative Studyhttps://www.pharmaradar360.com/article/clinical-factors-associated-with-anxiety-disorders-in-adults-with-childhood-hypo-f5f1bbf61b678653PharmaRadar360en2026-09-15T00:00:00.000ZClinical Factors Associated with Anxiety Disorders in Adults with Childhood Hypospadias Repair: Results from the F.R.E.S.H. Studyhttps://www.pharmaradar360.com/article/single-bolus-sequential-triple-rule-out-ct-angiography-image-quality-and-radiati-2523fc6a940efa2aPharmaRadar360en2026-09-15T00:00:00.000ZSingle-Bolus Sequential Triple-Rule-Out CT Angiography: Image Quality and Radiation Dose on Wide-Area Detector and Dual-Source CThttps://www.pharmaradar360.com/article/is-there-a-way-to-break-the-glass-ceiling-in-the-diagnosis-and-treatment-of-extr-6dbfbb9ae0d485dbPharmaRadar360en2026-09-15T00:00:00.000ZIs There a Way to Break the Glass Ceiling in the Diagnosis and Treatment of Extraintestinal Manifestations (EIMs) in the Course of Inflammatory Bowel Diseases? A Comprehensive Review of Diagnosis, Pathophysiology, and Treatment of EIMhttps://www.pharmaradar360.com/article/psychometric-evaluation-of-the-romanian-quality-of-life-in-adult-cancer-survivor-e4c61b7530a11b5dPharmaRadar360en2026-09-15T00:00:00.000ZPsychometric Evaluation of the Romanian Quality of Life in Adult Cancer Survivors (QLACS) in Women with Breast Cancer: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/clinical-decision-making-after-receptor-conversion-following-neoadjuvant-therapy-f9281e61f8e9684dPharmaRadar360en2026-09-15T00:00:00.000ZClinical Decision-Making After Receptor Conversion Following Neoadjuvant Therapy in Breast Cancer: A Three-Strategy Frameworkhttps://www.pharmaradar360.com/article/hematological-versus-clinical-predictors-of-tumor-grade-in-endometrial-cancer-a-89a0af042aa922ccPharmaRadar360en2026-09-15T00:00:00.000ZHematological Versus Clinical Predictors of Tumor Grade in Endometrial Cancer: A Comparative Machine Learning Study with SHAP-Based Explainabilityhttps://www.pharmaradar360.com/article/pathological-complete-response-and-residual-disease-patterns-after-neoadjuvant-c-938b06a557f15426PharmaRadar360en2026-09-15T00:00:00.000ZPathological Complete Response and Residual Disease Patterns After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: Clinical and Laboratory Associationshttps://www.pharmaradar360.com/article/psoas-compartment-block-versus-medial-branch-block-for-low-back-pain-a-narrative-c097443763d57ce9PharmaRadar360en2026-09-15T00:00:00.000ZPsoas Compartment Block Versus Medial Branch Block for Low Back Pain: A Narrative Review of Anatomical Targets, Clinical Evidence, and Patient Selectionhttps://www.pharmaradar360.com/article/serum-bdnf-in-subacute-stroke-effects-of-a-four-week-aerobic-exercise-interventi-4795366c5aa72614PharmaRadar360en2026-09-15T00:00:00.000ZSerum BDNF in subacute stroke: effects of a four-week aerobic exercise intervention in the PHYS-STROKE trialhttps://www.pharmaradar360.com/article/psilocybin-and-ayahuasca-in-treatment-resistant-depression-clinical-evidence-met-a68c95b0c85d72baPharmaRadar360en2026-09-15T00:00:00.000ZPsilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative review